Brokerages Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00

Precigen, Inc. (NASDAQ:PGEN) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $7.00.

Several research analysts have weighed in on PGEN shares. JMP Securities lowered their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Precigen in a research report on Friday, November 15th.

Precigen Price Performance

Shares of Precigen stock opened at $0.77 on Friday. Precigen has a 1-year low of $0.76 and a 1-year high of $1.93. The stock has a market cap of $226.39 million, a P/E ratio of -1.46 and a beta of 1.71. The stock’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $1.20.

Institutional Investors Weigh In On Precigen

Several large investors have recently bought and sold shares of PGEN. Traphagen Investment Advisors LLC acquired a new position in shares of Precigen during the 3rd quarter worth about $29,000. Stifel Financial Corp raised its holdings in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares in the last quarter. AQR Capital Management LLC raised its stake in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Precigen by 86.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 25,681 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.